Immunovant Inc (NASDAQ: IMVT) on Tuesday, plunged -3.40% from the previous trading day, before settling in for the closing price of $20.30. Within the past 52 weeks, IMVT’s price has moved between $17.65 and $35.97.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -49.95%. With a float of $69.35 million, this company’s outstanding shares have now reached $147.20 million.
Let’s determine the extent of company efficiency that accounts for 207 employees. In terms of profitability, gross margin is 90.4%, operating margin of -27013.67%, and the pretax margin is -25478.07%.
Immunovant Inc (IMVT) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Immunovant Inc is 59.17%, while institutional ownership is 47.38%. The most recent insider transaction that took place on Mar 07 ’25, was worth 156,769. In this transaction Director of this company sold 8,000 shares at a rate of $19.60, taking the stock ownership to the 91,913 shares. Before that another transaction happened on Mar 07 ’25, when Company’s Director proposed sale 8,000 for $19.52, making the entire transaction worth $156,160.
Immunovant Inc (IMVT) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.74 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -49.95% per share during the next fiscal year.
Immunovant Inc (NASDAQ: IMVT) Trading Performance Indicators
Immunovant Inc (IMVT) is currently performing well based on its current performance indicators. A quick ratio of 6.04 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.62, a number that is poised to hit -0.71 in the next quarter and is forecasted to reach -3.03 in one year’s time.
Technical Analysis of Immunovant Inc (IMVT)
Looking closely at Immunovant Inc (NASDAQ: IMVT), its last 5-days average volume was 0.95 million, which is a drop from its year-to-date volume of 1.24 million. As of the previous 9 days, the stock’s Stochastic %D was 73.86%. Additionally, its Average True Range was 1.08.
During the past 100 days, Immunovant Inc’s (IMVT) raw stochastic average was set at 13.56%, which indicates a significant decrease from 48.88% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 62.31% in the past 14 days, which was higher than the 48.45% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $21.80, while its 200-day Moving Average is $26.93. However, in the short run, Immunovant Inc’s stock first resistance to watch stands at $20.18. Second resistance stands at $20.74. The third major resistance level sits at $21.14. If the price goes on to break the first support level at $19.22, it is likely to go to the next support level at $18.82. Should the price break the second support level, the third support level stands at $18.26.
Immunovant Inc (NASDAQ: IMVT) Key Stats
Market capitalization of the company is 3.33 billion based on 169,861K outstanding shares. Right now, sales total 0 K and income totals -259,340 K. The company made 0 K in profit during its latest quarter, and -111,120 K in sales during its previous quarter.
